CVS three-lens brief
Evidence-based stock research on CVS. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $96.58 — 24% above current (26 analysts). · Debt-to-equity of 106.1 — balance-sheet-heavy.
- Analyst mean target $96.58 — 24% above current (26 analysts).
- Debt-to-equity of 106.1 — balance-sheet-heavy.
CVS closed at $77.94 (-1.17%) as of 2026-04-25. Market cap: $99.89B. P/E (trailing) 56.1. Positives: analyst mean target $96.58 — 24% above current (26 analysts).. Concerns: debt-to-equity of 106.1 — balance-sheet-heavy.. Last quarter: Revenue $105.69B, net income $2.94B, free cash flow $5.93B.
Why three lenses on CVS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CVSacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CVS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CVS brief"></iframe>